skip to content
Primary navigation


Drug - Zytiga (abiraterone acetate) [Centocor Ortho Biotech]

February 2013

Therapeutic Area - Oral Oncology

Approval criteria

  • Patient has metastatic castration-resistant prostate cancer AND
  • Will be on prednisone concurrently AND
  • Has had previous chemotherapy with docetaxel OR
  • Is not a chemotherapy candidate and in the pre-docetaxel setting

Quantity limits

The initial PA will allow a first fill of 14 days [56 tablets (4 tablets once daily)] with one refill to ensure patient tolerance with therapy before approving in larger, monthly quantities.

Monthly Quantity Limit = 136

Background information

Zytiga (abiraterone acetate) is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer (CRPC) who have previously received chemotherapy containing docetaxel.  

The 1.2013 NCCN guidelines for prostate cancer place abiraterone acetate as an alternative to ketoconazole for patients with metastatic disease without symptomatic visceral disease, or after docetaxel in patients with symptomatic visceral disease. Imitinib is considered first-line treatment.


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top